Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?
作者信息
Wang Sue-Jane, Fotenos Anthony, Masters Shane C, Marzella Louis
机构信息
Division of Biometrics I, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
Division of Imaging and Radiation Medicine, Office of Specialty Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration.
出版信息
Theranostics. 2022 Mar 28;12(7):3079-3083. doi: 10.7150/thno.71788. eCollection 2022.
Abstract
摘要
相似文献
1
Theranostics approach in drug development: is there study efficiency when the prevalence of the molecular target is very high?
Theranostics. 2022 Mar 28;12(7):3079-3083. doi: 10.7150/thno.71788. eCollection 2022.
2
Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1595. doi: 10.1002/wnan.1595. Epub 2019 Oct 23.
3
Ultrasound-based nanomedicine for molecular imaging of prostate cancer: from diagnostics to theranostics.
Nanomedicine (Lond). 2021 Oct;16(23):2029-2032. doi: 10.2217/nnm-2021-0170. Epub 2021 Sep 14.
4
Theranostics and precision medicine special feature.
Br J Radiol. 2018 Nov;91(1091):20189004. doi: 10.1259/bjr.20189004.
5
Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Radiographics. 2020 Oct;40(6):1715-1740. doi: 10.1148/rg.2020200021.
6
Hybrid nanogels with unique designs for improved tumor theranostics.
Nanomedicine (Lond). 2020 Jun;15(15):1455-1458. doi: 10.2217/nnm-2020-0142. Epub 2020 Jun 9.
7
General Concepts in Theranostics.
PET Clin. 2021 Jul;16(3):313-326. doi: 10.1016/j.cpet.2021.03.010.
8
Recent Advances in Theranostic Applications of Nanomaterials in Cancer.
Curr Pharm Des. 2022;28(2):133-150. doi: 10.2174/1381612827666210916140627.
9
Nuclear medicine theranostics comes of age.
Lancet Oncol. 2021 Nov;22(11):1497-1498. doi: 10.1016/S1470-2045(21)00540-4.
10
The ICPO Foundation-on the way toward collaborative growth of theranostics.
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):443-444. doi: 10.1007/s00259-021-05651-2.
引用本文的文献
1
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875.
2
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of imaging.
Theranostics. 2022 Oct 24;12(17):7509-7531. doi: 10.7150/thno.77259. eCollection 2022.
本文引用的文献
1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
2
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Front Oncol. 2021 Feb 18;11:630589. doi: 10.3389/fonc.2021.630589. eCollection 2021.
3
Recent advances in clinical trial design considerations in Thera"nostics".
Contemp Clin Trials. 2020 Sep;96:106100. doi: 10.1016/j.cct.2020.106100. Epub 2020 Aug 5.
4
Radiotheranostics: a roadmap for future development.
Lancet Oncol. 2020 Mar;21(3):e146-e156. doi: 10.1016/S1470-2045(19)30821-6.
5
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Theranostics. 2020 Jan 1;10(4):1678-1693. doi: 10.7150/thno.40482. eCollection 2020.
6
TheraP: a randomized phase 2 trial of Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
BJU Int. 2019 Nov;124 Suppl 1:5-13. doi: 10.1111/bju.14876. Epub 2019 Oct 22.
7
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-labelled PSMA Radioligand Therapy.
Eur Urol Oncol. 2019 Nov;2(6):670-676. doi: 10.1016/j.euo.2018.11.007. Epub 2018 Dec 13.
8
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Eur Urol. 2019 Oct;76(4):469-478. doi: 10.1016/j.eururo.2019.06.030. Epub 2019 Jul 22.
9
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.
10
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
Endocr Relat Cancer. 2018 Nov 23;26(2):131-146. doi: 10.1530/ERC-18-0226.
Zotero 插件